Exscientia plc (NASDAQ:EXAI – Get Free Report) saw a significant increase in short interest in the month of August. As of August 15th, there was short interest totalling 3,690,000 shares, an increase of 15.7% from the July 31st total of 3,190,000 shares. Based on an average trading volume of 593,200 shares, the days-to-cover ratio is presently 6.2 days. Approximately 3.5% of the company’s stock are sold short.
Exscientia Stock Down 1.8 %
Exscientia stock traded down $0.10 during trading hours on Monday, reaching $5.56. The stock had a trading volume of 752,700 shares, compared to its average volume of 637,763. Exscientia has a 52 week low of $3.80 and a 52 week high of $7.91. The company has a market cap of $672.13 million, a price-to-earnings ratio of -4.24 and a beta of 0.85. The company has a debt-to-equity ratio of 0.06, a current ratio of 5.93 and a quick ratio of 5.93. The business’s 50 day moving average price is $5.33 and its 200-day moving average price is $5.35.
Exscientia (NASDAQ:EXAI – Get Free Report) last posted its quarterly earnings data on Thursday, August 15th. The company reported ($0.36) EPS for the quarter, missing the consensus estimate of ($0.31) by ($0.05). The firm had revenue of $5.60 million for the quarter. Exscientia had a negative return on equity of 37.56% and a negative net margin of 620.99%. Sell-side analysts anticipate that Exscientia will post -1.25 EPS for the current year.
Wall Street Analysts Forecast Growth
Check Out Our Latest Analysis on Exscientia
Hedge Funds Weigh In On Exscientia
Large investors have recently made changes to their positions in the business. Novo Holdings A S acquired a new stake in Exscientia in the second quarter worth about $66,742,000. Susquehanna Fundamental Investments LLC purchased a new position in shares of Exscientia in the 2nd quarter valued at approximately $256,000. Vanguard Personalized Indexing Management LLC acquired a new stake in Exscientia in the 2nd quarter worth approximately $54,000. Federated Hermes Inc. acquired a new stake in Exscientia in the 2nd quarter worth approximately $115,000. Finally, Bank of New York Mellon Corp grew its position in Exscientia by 108.8% during the 2nd quarter. Bank of New York Mellon Corp now owns 388,459 shares of the company’s stock worth $1,981,000 after purchasing an additional 202,377 shares during the last quarter. 41.58% of the stock is owned by institutional investors and hedge funds.
About Exscientia
Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company's lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy.
See Also
- Five stocks we like better than Exscientia
- How to Read Stock Charts for Beginners
- Autodesk Stock: Analysts’ Top AI Pick You Shouldn’t Overlook
- How Investors Can Find the Best Cheap Dividend Stocks
- Hidden Opportunities in Li Auto’s Tough Quarter You Can’t Miss
- Ride Out The Recession With These Dividend Kings
- Don’t Overlook Campbell Soup: Here’s What Could Drive Its Stock
Receive News & Ratings for Exscientia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exscientia and related companies with MarketBeat.com's FREE daily email newsletter.